The first trial to show a slowing in the progression of disability in secondary progressive multiple sclerosis (SPMS) has now been published online in The Lancet. The results of the EXPAND trial with ...
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed) Foralumab to advance into Phase 2 human ...
This month, Tiziana Life Sciences TLSA expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s ...
Samantha Salvaggio learned she had relapsing-remitting multiple sclerosis (RRMS) in 2005, when she was a 19-year-old sophomore at Ohio State University. Over the next 16 years, she averaged one ...
If you’ve been recently diagnosed with SPMS, you may wonder how the transition between RRMS and SPMS will affect your MS treatment options and lifestyle. Most people with MS are initially diagnosed ...
Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...
Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...
When you have inactive secondary-progressive multiple sclerosis (SPMS), it may seem like no news is good news. But the lack of relapses can be misleading. “Although things may seem ‘quiet,’ there may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results